论文部分内容阅读
目的探讨经皮肝穿射频消融和介入治疗在小肝癌患者治疗中的临床疗效。方法选择2012年4月至2014年4月接诊的80例小肝癌患者进行研究。按照随机数字表法分为观察组和对照组,每组40例。对照组采用传统手术切除治疗,观察组采用经皮肝穿射频消融联合介入治疗。术后随访记录两组患者的复发率和生存率。结果观察组术后12、24、36个月的复发率分别为12.50%、15.00%、27.50%,对照组分别为20.00%、35.00%、50.00%,观察组术后24、36个月的复发率均低于对照组(P<0.05)。观察组术后12、24、36个月的生存率分别为97.50%、90.00%、77.50%,对照组分别为85.00%、67.50%、55.00%,观察组术后24、36个月的生存率均高于对照组(P<0.05)。结论经皮肝穿射频消融和介入治疗联合治疗小肝癌具有显著的疗效,较传统手术切除预后好,值得临床广泛应用。
Objective To investigate the clinical efficacy of percutaneous transhepatic radiofrequency ablation and interventional therapy in the treatment of small liver cancer patients. Methods Eighty patients with small hepatocellular carcinoma admitted from April 2012 to April 2014 were studied. According to random number table divided into observation group and control group, 40 cases in each group. The control group was treated by conventional surgical resection. The observation group was treated by percutaneous transhepatic radiofrequency ablation combined with interventional therapy. Postoperative follow-up recorded two groups of patients relapse rate and survival rate. Results The recurrence rates at 12, 24 and 36 months after operation in the observation group were 12.50%, 15.00% and 27.50%, respectively. The control group was 20.00%, 35.00% and 50.00% respectively. The relapse rate was 24 and 36 months Rates were lower than the control group (P <0.05). Survival rates of observation group at 12, 24 and 36 months after operation were 97.50%, 90.00% and 77.50%, respectively, while those in control group were 85.00%, 67.50% and 55.00% respectively. Survival rates of observation group at 24 and 36 months All higher than the control group (P <0.05). Conclusion percutaneous transhepatic radiofrequency ablation and interventional treatment of small hepatocellular carcinoma has a significant effect, better prognosis than traditional surgical resection, it is widely used in clinical.